Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2018 2
2019 2
2020 4
2021 23
2022 8
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Mannent LP, Patel N, Staudinger HW, Yancopoulos GD, Mortensen ER, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM; BOREAS Investigators. Bhatt SP, et al. Among authors: robinson lb. N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21. N Engl J Med. 2023. PMID: 37272521 Clinical Trial.
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Patel N, Yancopoulos GD, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB; NOTUS Study Investigators. Bhatt SP, et al. Among authors: robinson lb. N Engl J Med. 2024 May 20. doi: 10.1056/NEJMoa2401304. Online ahead of print. N Engl J Med. 2024. PMID: 38767614
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.
Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Guilbert TW, Jackson DJ, Staudinger HW, Laws E, Mannent LP, Akinlade B, Maloney J, Tawo K, Khokhar FA, Li N, Hardin M, Abdulai RM, Lederer DJ, Robinson LB; Liberty Asthma EXCURSION Investigators. Bacharier LB, et al. Among authors: robinson lb. Lancet Respir Med. 2024 Jan;12(1):45-54. doi: 10.1016/S2213-2600(23)00303-X. Epub 2023 Nov 10. Lancet Respir Med. 2024. PMID: 37956679
Proton Pump Inhibitors in Allergy: Benefits and Risks.
Robinson LB, Ruffner MA. Robinson LB, et al. J Allergy Clin Immunol Pract. 2022 Dec;10(12):3117-3123. doi: 10.1016/j.jaip.2022.09.022. Epub 2022 Sep 23. J Allergy Clin Immunol Pract. 2022. PMID: 36162802 Free PMC article. Review.
Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018.
Miller RL, Shtessel M, Robinson LB, Banerji A. Miller RL, et al. Among authors: robinson lb. J Allergy Clin Immunol. 2019 Aug;144(2):381-392. doi: 10.1016/j.jaci.2019.06.010. Epub 2019 Jun 24. J Allergy Clin Immunol. 2019. PMID: 31247266 Free PMC article. Review.
Acute Allergic Reactions to mRNA COVID-19 Vaccines.
Blumenthal KG, Robinson LB, Camargo CA Jr, Shenoy ES, Banerji A, Landman AB, Wickner P. Blumenthal KG, et al. Among authors: robinson lb. JAMA. 2021 Apr 20;325(15):1562-1565. doi: 10.1001/jama.2021.3976. JAMA. 2021. PMID: 33683290 Free PMC article.
mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach.
Banerji A, Wickner PG, Saff R, Stone CA Jr, Robinson LB, Long AA, Wolfson AR, Williams P, Khan DA, Phillips E, Blumenthal KG. Banerji A, et al. Among authors: robinson lb. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1423-1437. doi: 10.1016/j.jaip.2020.12.047. Epub 2020 Dec 31. J Allergy Clin Immunol Pract. 2021. PMID: 33388478 Free PMC article. Review.
38 results